Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2022-06-06 Earnings Release
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Enhertu efficacy results in HER2-low breast cancer
Earnings Release Classification · 90% confidence The document is an official announcement from AstraZeneca PLC, dated June 6, 2022, identified by the RNS Number 6843N. It details the positive results from the DESTINY-Breast04 Phase III trial regarding the drug Enhertu for HER2-low metastatic breast cancer. The content is a press release summarizing clinical trial data, quoting key personnel, and providing detailed statistical tables. This format strongly suggests an immediate public disclosure of significant corporate or clinical news. Since it is not a full annual report (10-K), a formal audit report (AR), or a proxy statement (DEF 14A), and it is a direct announcement of results rather than a transcript (CT) or a general regulatory filing fallback (RNS), the most appropriate classification is Earnings Release (ER), as clinical trial results announcements often accompany or substitute for formal earnings releases when reporting major milestones. However, given the specific nature of clinical trial data disclosure, and the fact that it is a formal announcement of data that will be presented at a conference, it functions as a major corporate update. Since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is a clinical/scientific highlight, the closest fit among the options that capture immediate, material news is ER, or potentially RNS if it were less detailed. Because it contains substantial data and quotes, it is more than a simple RNS notice. Given the options, ER is the best fit for a major, immediate, data-driven corporate announcement, although it is not strictly financial earnings. If a 'Clinical Trial Update' category existed, that would be preferred. In the absence of that, this functions as a material event disclosure, similar in function to an ER. Q2 2022
2022-06-06 English
BLOCK LISTING INTERIM REVIEW
Foreign Filer Report
2022-06-01 English
TOTAL VOTING RIGHTS
Foreign Filer Report
2022-06-01 English
Block listing Interim Review
Regulatory Filings Classification · 98% confidence The document is a 'Block Listing Six Monthly Return' filed by AstraZeneca PLC via the London Stock Exchange's RNS service. This form reports the status of securities under various share option plans, detailing the balance of unallotted securities, increases, and issuances over a six-month period. While it relates to share capital, it is a standard regulatory disclosure required by the Listing Rules for block listings, which falls under the general regulatory filing category as it does not represent a new share issuance announcement (SHA) or a buyback (POS).
2022-06-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a notification released via RNS (London Stock Exchange news service) dated June 1, 2022. The content explicitly states it is a notification made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1, detailing the total number of voting rights (1,549,470,612) as of May 31, 2022. This type of regulatory disclosure regarding the total number of shares and voting rights falls under general regulatory announcements. While it relates to capital structure, it is not a financing event (CAP) or a share transaction (POS/SHA), but rather a mandatory periodic disclosure. Since it is a standard regulatory announcement provided via RNS that doesn't fit the more specific categories like DVA (Voting Results) or DIRS (Director's Dealing), the most appropriate classification is the general Regulatory Filings category (RNS). The document length is short (2770 chars), but it is a direct regulatory filing, not an announcement *about* a report.
2022-06-01 English
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2022-05-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.